

Pfizer Announces a Research Grant RFP

Pre-clinical & Translational Research in Multiple Myeloma

Competitive Grant Program - internal Pfizer review process

I. Background

Pfizer Global Medical Grants (GMG) supports the global healthcare community's independent initiatives (e.g., research, quality improvement, or education) to improve patient outcomes in areas of unmet medical need that are aligned with Pfizer's medical and/or scientific strategies.

Pfizer's GMG competitive grant program involves a publicly posted general Request for Proposal (RFP) that provides detail regarding a general area of interest, sets timelines for review and approval, and uses an internal Pfizer review process to make final grant decisions. Organizations are invited to submit an application addressing the research gaps as outlined in the specific RFP.

For all Investigator Sponsored Research (ISRs) and general research grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, sponsorship, and conduct of the independent initiative supported by the grant, including compliance with any regulatory requirements. Pfizer must not be involved in any aspect of study protocol or project development, nor the conduct or monitoring of the research program.

II. Eligibility

Geographic Scope:	Global – all regions and countries included
Applicant Eligibility Criteria	• The institution and principal investigator (PI) must be based in one of the eligible countries noted above. • Only organizations are eligible to receive grants, not individuals or medical practice groups. • The applicant (PI) must have a medical or postdoctoral degree (MD, PhD, or equivalent), an advanced nursing degree (BSN with a MS/PhD), or a degree in Pharmacy. • Applicant must be affiliated with a host institution

III. Requirements

Date RFP Issued	July 30, 2021
Clinical Area	Oncology – Hematology – Multiple Myeloma
General Area of Interest for this RFP:	Only pre-clinical projects with a focus on these areas of interest will be considered for Pfizer support at this time: • Correlation between soluble B-cell Maturation Antigen (sBCMA) at baseline with FLC, M-spike, deepness of overall response, MRD-negativity, and response to prior therapy • Understanding the kinetics of sBCMA vs long-term responses (e.g., DoR, PFS, OS) in the context of bispecific treatment • Mechanisms of resistance (e.g., role of sBCMA in resistance/relapse; downregulation of membrane bound BCMA; T-cell exhaustion) • Correlation between Soluble BCMA and BCMA expression on myeloma cells (including assessment of gamma secretase activity) • Impact of prior treatment with BCMA-targeting agents on BCMA expression and sBCMA levels (including whether these prior treatments lead to BCMA mutations) • Mechanistic understanding of the impact of anti-myeloma agents (e.g., IMiDs, anti-CD38, proteasome inhibitors, dexamethasone) on elranatamab-mediated T-cell activation and anti-myeloma activity

	• Exploring in-vitro or in-vivo novel combinations with elranatamab (PF-06863135) with a focus on drugs that are not currently SOC in myeloma • Immunosuppressive mechanisms in the bone marrow that negatively impact bispecific (elranatamab) activity • Comparative analysis of bone marrow aspirate transcriptomes between responders and non-responders to elranatamab IMPORTANT NOTES: • Studies can be in-vitro or in-vivo or use existing patient samples (e.g. blood, bone marrow aspirates, etc.) • A limited amount of the Pfizer asset elranatamab (PF-06863135) is available and can be requested through this RFP for non-clinical studies
Expected Approximate Monetary Range of Grant Applications:	• Individual projects requesting up to $150,000 will be considered. The estimated total available budget related to this RFP is $500,000. • Compound-only requests (with no funding requested) may also come through this RFP • Proposals may be drug-only or funding-only or drug plus funding
Key Dates:	• RFP release date: July 30, 2021 • Full Proposal Grant Application due date: September 28, 2021 Please note the deadline is 23:59 Eastern Standard Time (e.g. New York, GMT -5). • Anticipated Grant Award Notification Date: November 15, 2021 • Grants will be distributed following a fully executed agreement. • Anticipated/Approximate Project Start and End Dates: Jan 2022 to Jan 2024 (study timelines may be shorter but no longer than 2 years)
How to Submit:	• Please go to www.cybergrants.com/pfizer/Research and sign in. First-time users should click “Create your password”. • In the application: o For the question “Are you replying to a Request for Proposal as part of the Competitive Grant Program?” select Yes o Select the following Competitive Grant Program Name: **2021 Oncology - Pre-clinical & Translational Research in Multiple Myeloma** o Select the following Primary Area of Interest: Oncology –

	Hematology – Multiple Myeloma • Requirements for submission: Complete all required sections of the online application and upload your project proposal (see Appendix) in the Proposal/Protocol field. • If you encounter any technical difficulties with the website, please click the "Technical Questions" link at the bottom of the page. **IMPORTANT:** Be advised applications submitted after the due date will not be reviewed under this RFP.
Questions:	• If you have questions regarding this RFP, please direct them in writing to the Grant Officer, [Jacqueline Waldrop (Jacqueline.Waldrop@pfizer.com), with the subject line "Pre-clinical & Translational Research in Multiple Myeloma." • Please click here to view Frequently Asked Questions regarding the Competitive Grant Program
Grant Agreements:	• If your grant is approved, your institution will be required to enter into a written grant agreement with Pfizer. Please click here to view the core terms of the agreement. • Pfizer has drafted the terms of these agreements to be balanced and reasonable and to further the goals of both parties. Negotiating grant agreements requires significant resources, so please ensure that your institution (including your legal department) is able and willing to abide by these terms before proceeding with submission of your application as they will need to be accepted in their entirety.
Review and Approval Process	• Grant requests received in response to a general RFP are reviewed by Pfizer to make final grant decisions.
Mechanism by which Applicants will be Notified:	• All applicants will be notified via email by the dates noted above. • Applicants may be asked for additional clarification during the review period.

Appendix A
General RFP Submission Requirements

Project Proposals/Protocols should be single-spaced using Calibri 12-point font and 1-inch margins. Please include the following:

Goals and Objectives	• Provide the main goal of the study and the study population (if applicable). Provide a detailed definition that is directly linked to the primary objective
Assessment of Need for the Project	• This should reflect your study rationale. Provide a brief description of the medical/scientific question and the rationale of how this trial or study addresses the question
Target Audience	• Describe the primary audience(s) targeted for this project. For Investigator Sponsored Clinical Trials, please specify the age, gender and other demographic information for trial population • Also indicate whom you believe will directly benefit from the project outcomes. Describe the overall population size as well as the size of your sample population
Project Design and Methods	• Describe concisely the research design and methods for achieving the stated goals. For a clinical interventional study, include inclusion/exclusion criteria, treatment plan and statistical plan
Innovation	• Explain what measures you have taken to assure that this project idea is original and does not duplicate other projects. Describe how this project builds upon existing work, pilot projects, or ongoing projects developed either by your institution or other institutions related to this project
Evaluation and Outcomes	• Specify type and frequency of safety, efficacy, and/or outcome measures. Also indicate the method(s) used to assess measures • Provide a publication plan describing intended submission of abstracts to (a) congress(es) or intended submission of (a) publication(s) to peer-reviewed journals. All publications must follow ICH guidelines
Anticipated Project Timeline	• Provide an anticipated timeline for your project including project start/end dates
Additional Information	• If there is any additional information you feel Pfizer should be aware of concerning the importance of this project, please summarize here • Early-career applicants: Letter(s) of support from mentor(s) and collaborators describing how the award will advance the applicant's career.

Organization Detail	• This information is used to assess the capability of the organizational resources available to perform the effort proposed. Identify the facilities to be used [laboratory, animal, clinical and "other"]. If appropriate, indicate their capacities, pertinent capabilities, relative proximity and extent of availability to the project
Budget Detail	• The budget amount requested must be in U.S. dollars (USD). • While estimating your budget please keep the following items in mind: o Institutional overhead and indirect costs may be included within the grant request. Examples include human resources department costs, payroll processing and accounting costs, janitorial services, utilities, property taxes, property and liability insurance, and building maintenance as well as additional project expenses such as costs for publication, IRB / IEC review fees, software license fees, and travel. Please note: Pfizer does not provide funding for capital equipment. o The inclusion of these costs cannot cause the amount requested to exceed the budget limit set forth in the RFP. o It should be noted that grants awarded through GMG cannot be used to purchase therapeutic agents (prescription or non-prescription). • Pfizer maintains a company-wide, maximum allowed overhead rate of 28% for independent studies and projects
References	• Bibliography of relevant references.